Ablation efficacy of 5-aminolevulinic acid-mediated photodynamic therapy on human glioma stem cells

Background: Cancer cells with stem cell-like features are generally more resistant to chemotherapy and radiotherapy than differentiated tumor cells. Thus, these cells tend to increase the propensity for tumor recurrence and metastasis. This study investigated the efficacy of 5-aminolevulinic acid-mediated photodynamic therapy (ALAPDT) in destructing glioma stem cells (GSCs), including the mesenchymal subtype (MES-GSCs) demonstrated to have the lowest radio- and chemosensitivity.Methods: Five high-grade glioma (HGG) GSC lines and derived differentiated glioma cell (DGC) lines were examined for protoporphyrin-IX (PpIX) expression using fluorescence-activated cell sorting (FACS) and then assessed for ALA-PDT sensitivity using cell viability assays. MES-GSCs surviving ALA-PDT were then isolated and evaluated for stem cell and mesenchymal marker expression levels (CD44, ALDH1A3, KLF4, nestin) by qRT-PCR. The ability of these surviving cells to form tumors was then examined using colony forming and by xenograft tumor assays in athymic mice. Finally, the relationship between PpIX expression level (high versus low) and ALAPDT sensitivity was examined by FACS and colony forming assays.Results: ALA-PDT was effective against all GSC lines including MES-GSCs. MES-GSC lines exhibited higher PpIX expression than derived DGCs. Surviving MES-GSCs demonstrated lower stem cell marker expression and tumor forming potential than naive MES-GSCs. Higher PpIX production capacity by MES-GSCs was associated with greater colony forming ability, and ALA-PDT was more effective against MES-GSCs with greater PpIX accumulation.Conclusion: ALA-PDT may be clinically effective against HGG by targeting GSCs, including MES-GSCs.

Automated summary

This study investigated the efficacy of ALA-PDT in destructing GSCs, including the MES-GSCs which have the lowest sensitivity to radiotherapy and chemotherapy. The results showed that ALA-PDT was effective against all GSC lines, and MES-GSCs exhibited higher PpIX expression than DGCs. Surviving MES-GSCs had lower stem cell marker expression and tumor forming potential. Thus, ALA-PDT may be clinically effective against HGG by targeting GSCs, including MES-GSCs.